Tags

Type your tag names separated by a space and hit enter

A six-month study of pergolide and levodopa in de novo Parkinson's disease patients.
Clin Neuropharmacol. 1998 Nov-Dec; 21(6):358-62.CN

Abstract

Formal studies examining the antiparkinsonian efficacy of levodopa and pergolide monotherapy in de novo Parkinson's disease (PD) are lacking. The authors conducted a preliminary, 6-month, open-label parallel experimental study with de novo consecutive PD patients who were randomly assigned to three daily doses of pergolide (n = 10; mean age, 63.7 years; mean Hohen & Yahr score, 1.5; mean final dose, 2.8 mg daily) or levodopa (n = 10; mean age, 67.3 years; mean Hohen & Yahr score, 1.8; mean final dose, 435 mg daily). Doses were titrated individually according to patients' evaluation of their own functional ability, known side-effects, and a monthly administration of the Unified Parkinson's Disease Rating Scale (UPDRS) by a clinician blind to the treatment regime. All patients completed the study. There were no significant basal differences between groups and no significant treatment ortreatment-by-time effects in UPDRS scores (according to two-way ANOVA). A clear time effect was observed for most of the functional and motor variables (p < 0.001), with significant improvement during the first month that was maintained for the duration of the study in both groups. Side effects were mild, transient, and comparable. In this preliminary study, pergolide and levodopa exhibited similar symptomatic efficacy and incidence of side effects in the short-term treatment of de novo PD patients at their usual age of clinical manifestation.

Authors+Show Affiliations

Department of Neurology, Sant Pau Hospital, Barcelona, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9844794

Citation

Kulisevsky, J, et al. "A Six-month Study of Pergolide and Levodopa in De Novo Parkinson's Disease Patients." Clinical Neuropharmacology, vol. 21, no. 6, 1998, pp. 358-62.
Kulisevsky J, López-Villegas D, García-Sánchez C, et al. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients. Clin Neuropharmacol. 1998;21(6):358-62.
Kulisevsky, J., López-Villegas, D., García-Sánchez, C., Barbanoj, M., Gironell, A., & Pascual-Sedano, B. (1998). A six-month study of pergolide and levodopa in de novo Parkinson's disease patients. Clinical Neuropharmacology, 21(6), 358-62.
Kulisevsky J, et al. A Six-month Study of Pergolide and Levodopa in De Novo Parkinson's Disease Patients. Clin Neuropharmacol. 1998 Nov-Dec;21(6):358-62. PubMed PMID: 9844794.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A six-month study of pergolide and levodopa in de novo Parkinson's disease patients. AU - Kulisevsky,J, AU - López-Villegas,D, AU - García-Sánchez,C, AU - Barbanoj,M, AU - Gironell,A, AU - Pascual-Sedano,B, PY - 1998/12/9/pubmed PY - 1998/12/9/medline PY - 1998/12/9/entrez SP - 358 EP - 62 JF - Clinical neuropharmacology JO - Clin Neuropharmacol VL - 21 IS - 6 N2 - Formal studies examining the antiparkinsonian efficacy of levodopa and pergolide monotherapy in de novo Parkinson's disease (PD) are lacking. The authors conducted a preliminary, 6-month, open-label parallel experimental study with de novo consecutive PD patients who were randomly assigned to three daily doses of pergolide (n = 10; mean age, 63.7 years; mean Hohen & Yahr score, 1.5; mean final dose, 2.8 mg daily) or levodopa (n = 10; mean age, 67.3 years; mean Hohen & Yahr score, 1.8; mean final dose, 435 mg daily). Doses were titrated individually according to patients' evaluation of their own functional ability, known side-effects, and a monthly administration of the Unified Parkinson's Disease Rating Scale (UPDRS) by a clinician blind to the treatment regime. All patients completed the study. There were no significant basal differences between groups and no significant treatment ortreatment-by-time effects in UPDRS scores (according to two-way ANOVA). A clear time effect was observed for most of the functional and motor variables (p < 0.001), with significant improvement during the first month that was maintained for the duration of the study in both groups. Side effects were mild, transient, and comparable. In this preliminary study, pergolide and levodopa exhibited similar symptomatic efficacy and incidence of side effects in the short-term treatment of de novo PD patients at their usual age of clinical manifestation. SN - 0362-5664 UR - https://www.unboundmedicine.com/medline/citation/9844794/A_six_month_study_of_pergolide_and_levodopa_in_de_novo_Parkinson's_disease_patients_ DB - PRIME DP - Unbound Medicine ER -